Biological and Clinical Implications of Comorbidities in Parkinson's Disease

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2017 Dec 20

PMID 29255414

Citations 48

Authors

Jose A Santiago

Virginie Bottero

Judith A Potashkin

Affiliations

Soon will be listed here.

Abstract

A wide spectrum of comorbidities has been associated with Parkinson's disease (PD), a progressive neurodegenerative disease that affects more than seven million people worldwide. Emerging evidence indicates that chronic diseases including diabetes, depression, anemia and cancer may be implicated in the pathogenesis and progression of PD. Recent epidemiological studies suggest that some of these comorbidities may increase the risk of PD and precede the onset of motor symptoms. Further, drugs to treat diabetes and cancer have elicited neuroprotective effects in PD models. Nonetheless, the mechanisms underlying the occurrence of these comorbidities remain elusive. Herein, we discuss the biological and clinical implications of comorbidities in the pathogenesis, progression, and clinical management, with an emphasis on personalized medicine applications for PD.

Citing Articles

Retrospective database analysis on the demographics and resource utilization of patients with Parkinson's disease in Quebec, Canada.

Baribeau V, Mohammed S, Awan A, Parison D, Lachaine J Clin Park Relat Disord. 2025; 12:100300.

PMID: 39911313 PMC: 11795128. DOI: 10.1016/j.prdoa.2025.100300.

Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives.

Tenchov R, Sasso J, Zhou Q ACS Omega. 2025; 10(2):1864-1892.

PMID: 39866628 PMC: 11755173. DOI: 10.1021/acsomega.4c09114.

Paulamaki J, Jyrkka J, Hyttinen-Huotari V, Huhtala H, Jamsen E Basic Clin Pharmacol Toxicol. 2025; 136(2):e14125.

PMID: 39780521 PMC: 11712029. DOI: 10.1111/bcpt.14125.

"Ups and Downs, Joys and Sorrows" - Assessment and Clinical Relevance of Patient Priorities in an Interdisciplinary Parkinson's Disease Clinic.

Trahairv E, Allen A, Mantri S J Patient Cent Res Rev. 2024; 11(3):186-196.

PMID: 39439538 PMC: 11493310. DOI: 10.17294/2330-0698.2078.

Cohort-specific boolean models highlight different regulatory modules during Parkinson's disease progression.

Hemedan A, Satagopam V, Schneider R, Ostaszewski M iScience. 2024; 27(10):110956.

PMID: 39429779 PMC: 11489052. DOI: 10.1016/j.isci.2024.110956.

References

Deng Q, Zhou X, Chen J, Pan M, Gao H, Zhou J . Lower hemoglobin levels in patients with parkinson's disease are associated with disease severity and iron metabolism. Brain Res. 2016; 1655:145-151. DOI: 10.1016/j.brainres.2016.11.007. View

Sandyk R . The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci. 1993; 69(1-4):125-30. DOI: 10.3109/00207459309003322. View

Li W, Zhang H, Guo Q, Wu X, Xu Z, Dang C . Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer. Dis Markers. 2015; 2015:657570. PMC: 4353443. DOI: 10.1155/2015/657570. View

Hoogendijk W, Sommer I, Tissingh G, Deeg D, Wolters E . Depression in Parkinson's disease. The impact of symptom overlap on prevalence. Psychosomatics. 1998; 39(5):416-21. DOI: 10.1016/S0033-3182(98)71300-3. View

Erro R, Spina E, Barone P, Pellecchia M . On the relationship between side of onset and cognition in Parkinson disease. Parkinsonism Relat Disord. 2015; 21(11):1391-2. DOI: 10.1016/j.parkreldis.2015.09.052. View

Feng D, Cai W, Chen X . The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener. 2015; 4:20. PMC: 4620601. DOI: 10.1186/s40035-015-0043-z. View

Venda L, Cragg S, Buchman V, Wade-Martins R . α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2010; 33(12):559-68. PMC: 3631137. DOI: 10.1016/j.tins.2010.09.004. View

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

Kwon K, Kang S, Kim M, Lee H, Jang J, Kim J . Nonmotor Symptoms and Cognitive Decline in de novo Parkinson's Disease. Can J Neurol Sci. 2014; 41(5):597-602. DOI: 10.1017/cjn.2014.3. View

10.

Ascherio A, Schwarzschild M . The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016; 15(12):1257-1272. DOI: 10.1016/S1474-4422(16)30230-7. View

11.

Benedetti M, Maraganore D, Bower J, McDonnell S, Peterson B, Ahlskog J . Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord. 2001; 16(5):830-7. DOI: 10.1002/mds.1170. View

12.

Tang C, Lu M, Muo C, Tsai C, Kao C . Increased risk of brain tumor in patients with Parkinson's disease: a nationwide cohort study in Taiwan. Acta Neurol Scand. 2015; 134(2):148-53. DOI: 10.1111/ane.12524. View

13.

Sampson T, Debelius J, Thron T, Janssen S, Shastri G, Ilhan Z . Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016; 167(6):1469-1480.e12. PMC: 5718049. DOI: 10.1016/j.cell.2016.11.018. View

14.

Peters R, Burch L, Warner J, Beckett N, Poulter R, Bulpitt C . Haemoglobin, anaemia, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr. 2008; 8:18. PMC: 2529275. DOI: 10.1186/1471-2318-8-18. View

15.

Ye R, Shen T, Jiang Y, Xu L, Si X, Zhang B . The Relationship between Parkinson Disease and Brain Tumor: A Meta-Analysis. PLoS One. 2016; 11(10):e0164388. PMC: 5072611. DOI: 10.1371/journal.pone.0164388. View

16.

Postuma R, Aarsland D, Barone P, Burn D, Hawkes C, Oertel W . Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord. 2012; 27(5):617-26. DOI: 10.1002/mds.24996. View

17.

Guerreiro R, Bras J, Santana I, Januario C, Santiago B, Morgadinho A . Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 2006; 6:24. PMC: 1534050. DOI: 10.1186/1471-2377-6-24. View

18.

Zeng H, Qu Y, Zhang W, Xiu B, Deng A, Liang A . Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer. Int J Mol Sci. 2011; 12(6):3489-99. PMC: 3131574. DOI: 10.3390/ijms12063489. View

19.

Ruiz-Martinez J, de la Riva P, Rodriguez-Oroz M, Mondragon Rezola E, Bergareche A, Gorostidi A . Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. Mov Disord. 2013; 29(6):750-5. DOI: 10.1002/mds.25778. View

20.

Mittal S, Bjornevik K, Im D, Flierl A, Dong X, Locascio J . β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science. 2017; 357(6354):891-898. PMC: 5761666. DOI: 10.1126/science.aaf3934. View